Table II.
Frequencies of c-MYC and other biomarkers in the primary tumor components (n=80).
| Primary tumor, no. (%) | ||
|---|---|---|
| Markers | Epithelium | Stroma |
| c-MYC (cyt) | ||
| Negative | 2 (2.5) | 3 (3.8) |
| Positive | 77 (96.3) | 77 (96.2) |
| Missing | 1 (1.2) | 0 (0.0) |
| c-MYC (nuc) | ||
| Negative | 10 (12.5) | 5 (6.3) |
| Positive | 69 (86.3) | 75 (93.7) |
| Missing | 1 (1.2) | 0 (0.0) |
| ER | ||
| Negative | 44 (55.0) | 71 (88.8) |
| Positive | 34 (42.5) | 0 (0.0) |
| Missing | 2 (2.5) | 9 (11.2) |
| PR | ||
| Negative | 41 (51.2) | 77 (96.2) |
| Positive | 29 (36.3) | 0 (0.0) |
| Missing | 10 (12.5) | 3 (3.8) |
| HER2 | ||
| Negative | 61 (76.2) | 76 (95.0) |
| Positive | 17 (21.3) | 0 (0.0) |
| Missing | 2 (2.5) | 4 (5.0) |
| EGFR | ||
| Negative | 75 (93.7) | 78 (97.5) |
| Positive | 3 (3.8) | 0 (0.0) |
| Missing | 2 (2.5) | 2 (2.5) |
| p53 | ||
| Negative | 49 (61.3) | 75 (93.7) |
| Positive | 25 (31.2) | 0 (0.0) |
| Missing | 6 (7.5) | 5 (6.3) |
| Ki67 | ||
| Negative | 57 (71.3) | 76 (95.0) |
| Positive | 17 (21.3) | 0 (0.0) |
| Missing | 6 (7.4) | 4 (5.0) |
| mTOR | ||
| Negative | 41 (51.3) | 45 (56.2) |
| Positive | 38 (47.5) | 35 (43.8) |
| Missing | 1 (1.2) | 0 (0.0) |
| p-AKT | ||
| Negative | 17 (21.3) | 24 (30.0) |
| Positive | 63 (78.7) | 56 (70.0) |
| Missing | 0 (0.0) | 0 (0.0) |
Cyt, cytoplasmic; nuc, nuclear; EGFR, epidermal growth factor receptor; p-AKT, phospho-AKT; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; mTOR, mammalian target of rapamycin.